Get the Stockscreener App
96.95
1.36%
1.36
After Hours:
96.74
-0.21
-0.22%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $96.95, with a volume of 4.66M.
It is up +1.36% in the last 24 hours and up +5.30% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$95.59
Open:
$96.56
24h Volume:
4.66M
Relative Volume:
0.74
Market Cap:
$120.48B
Revenue:
$28.30B
Net Income/Loss:
$126.00M
P/E Ratio:
1,077.22
EPS:
0.09
Net Cash Flow:
$9.43B
1W Performance:
+4.27%
1M Performance:
+5.30%
6M Performance:
+24.14%
1Y Performance:
+23.24%
1-Day Range:
$95.44
$96.97
1-Week Range:
$92.26
$96.95
52-Week Range:
$62.07
$98.90
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
96.95 | 120.48B | 28.30B | 126.00M | 9.43B | 0.09 |
|
LLY
Lilly Eli Co
|
823.23 | 778.66B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.34 | 379.90B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
152.87 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
175.59 | 310.55B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Cognizant to Provide Gilead With AI-Driven Tools Under Expanded Partnership -January 30, 2025 at 09:12 am EST - Marketscreener.com
Cognizant Expands Partnership with Gilead - Contract Pharma
Cognizant expands AI services for Gilead Sciences - Investing.com
Cognizant's Next-Gen AI Platform Powers Gilead Sciences' $Billion Technology Overhaul - StockTitan
Baader Bank Aktiengesellschaft Buys 7,328 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Milestone Asset Management LLC Has $2.06 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b - GlobeNewswire
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Hantz Financial Services Inc. - MarketBeat
Mayflower Financial Advisors LLC Takes $317,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences' SWOT analysis: stock outlook shaped by HIV and oncology progress - Investing.com
Gilead Shines Some Light On Its Inflammation Ambitions - News & Insights
Gilead Worker Accused of Sex Harassment Advances Defamation Suit - Bloomberg Law
Looking At Gilead Sciences's Recent Unusual Options Activity - Benzinga
Swedbank AB Buys 54,360 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Forsta AP Fonden Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Breaking Down Gilead Sciences: 22 Analysts Share Their Views - Benzinga
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Yahoo Finance
Twelve Points Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
SteelPeak Wealth LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
JPMorgan Adjusts Price Target on Gilead Sciences to $115 From $105, Maintains Overweight Rating - Marketscreener.com
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025 - BioSpace
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views? - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Decreased by Matrix Asset Advisors Inc. NY - MarketBeat
Foundations Investment Advisors LLC Acquires 13,417 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Union Bancaire Privee UBP SA Invests $1.55 Million in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Kingswood Wealth Advisors LLC Sells 7,735 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Drive Wealth Management LLC Takes $290,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years - Benzinga
Pacer Advisors Inc. Has $594.37 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
KBC Group NV Decreases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Strategic Investment Advisors MI Decreases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $13.13 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Marshall Financial Group LLC Trims Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Moody Lynn & Lieberson LLC Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Janney Montgomery Scott LLC - MarketBeat
AEGON ASSET MANAGEMENT UK Plc Has $24.70 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Dynamic Advisor Solutions LLC Sells 5,449 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Avior Wealth Management LLC Purchases 3,129 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Bartlett & CO. Wealth Management LLC Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Why Gilead Sciences (GILD) Is One of the Best Humane Stocks to Invest in Now? - Insider Monkey
Exchange Traded Concepts LLC Raises Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
CX Institutional Has $5.94 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Oliver Luxxe Assets LLC Invests $4.46 Million in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Trimmed by MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Cerro Pacific Wealth Advisors LLC - MarketBeat
Veracity Capital LLC Boosts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
2,815 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Advisory Alpha LLC - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) is Donoghue Forlines LLC's 6th Largest Position - MarketBeat
Beacon Investment Advisory Services Inc. Has $7.41 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):